NICE requests Biogen to submit Spinraza for single technology appraisal as a treatment for spinal muscular atrophy.

The National Institute for Health and Care Excellence (NICE) has formally invited Biogen to submit Spinraza (nusinersen) for Single Technology Appraisal (STA) on its course toward possible NHS funding. Spinraza is the first approved spinal muscular atrophy (SMA) treatment in the E.U., the United States, and other countries.

NICE and England�s National Health Service (NHS) are also developing a Managed Access Agreement, which reassures Biogen that there is a long-term reimbursement path for Spinraza in England. Technology appraisals are recommendations based on clinical and economic evidence for the use of new and existing medicines and treatments within the NHS. An STA covers a single technology for a single indication.